drugset / Trial / NCT02605694
Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase II study to evaluate the efficacy and safety of DR vs R-CHOP in subjects with relapsed/refractory FL
Timeline
- Start
- 2015-12
- Primary completion
- 2016-11
- Completion
- 2016-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | Duvelisib | Small molecule | 25 mg | Oral |
| Comparator | Prednisone | Other / unclassified | 100 mg | Oral |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |